XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table

PAY VERSUS PERFORMANCE

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation and certain financial performance of our Company. The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the Committee view the link between the Company’s performance and its NEOs’ pay. For additional information on our compensation programs and philosophy and how we design our compensation programs to align pay with performance, see the section titled “Compensation Discussion and Analysis.”

The table below presents information on the compensation of our chief executive officer(s) and our other NEOs in comparison to certain performance metrics for 2024, 2023, 2022, 2021 and 2020:

 

 

Summary compensation table total for first PEO

 

 

Summary compensation table total for second PEO(2)(3)

 

 

Compensation actually paid to first PEO

 

 

Compensation actually paid to second PEO(2)(3)

 

 

Average summary compensation table total for non-PEO NEOs

 

 

Average compensation actually paid for non-PEO NEOs(2)(3)

 

 

Value of fixed $100 investment based on:

 

 

Net Income

 

 

Revenue

 

Year

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total shareholder return(4)

 

 

S&P 500 healthcare services total shareholder return(5)

 

 

 

 

 

 

 

2024

 

$

2,115,004

 

 

$

2,682,079

 

 

$

587,620

 

 

$

1,151,329

 

 

$

4,043,689

 

 

$

1,524,182

 

 

$

2

 

 

$

129

 

 

$

(212,638,000

)

 

$

254,364,000

 

2023

 

$

797,800

 

 

$

658,400

 

 

$

(9,131,552

)

 

$

(9,270,952

)

 

$

3,081,641

 

 

$

22,839

 

 

$

6

 

 

$

157

 

 

$

(679,200,000

)

 

$

259,047,000

 

2022

 

$

16,161,230

 

 

$

16,044,010

 

 

$

7,075,701

 

 

$

6,958,481

 

 

$

6,417,175

 

 

$

2,418,932

 

 

$

12

 

 

$

170

 

 

$

(272,100,000

)

 

$

277,190,000

 

2021

 

$

39,988,708

 

 

$

39,940,379

 

 

$

(26,819,435

)

 

$

(26,867,764

)

 

$

5,756,009

 

 

$

(3,538,060

)

 

$

26

 

 

$

162

 

 

$

(176,800,000

)

 

$

252,789,000

 

2020

 

$

69,253,101

 

 

$

69,247,314

 

 

$

96,113,239

 

 

$

96,107,452

 

 

$

9,574,620

 

 

$

21,760,358

 

 

$

110

 

 

$

119

 

 

$

(228,600,000

)

 

$

245,265,000

 

(1)
Amwell’s first principal executive officer for FY2020 through FY2024 was Dr. Ido Schoenberg. Amwell’s second principal executive officer for FY2020 through FY2024 was Dr. Roy Schoenberg. Amwell’s other, non-PEO, NEOs for FY2020 were Ms. Gotlib, Kurt Knight, and Mr. Anderson. Amwell’s other, non-PEO, NEOs for FY2021 were Ms. Gotlib, Mr. Shepardson, Mr. Knight, Mr. O’Grady, and Mr. Anderson. Amwell’s other, non-PEO, NEOs for FY2022 were Ms. Gotlib, Mr. Shepardson, Mr. Knight, and Mr. Paunovich. Amwell’s other, non-PEO, NEOs for FY2023 were Ms. Gotlib, Mr. Shepardson, Mr. Paunovich and Ms. Weiler. Amwell’s other, non-PEO, NEOs for FY2024 were Mr. Shepardson, Mr. Hirschhorn, Ms. Gotlib,Mr. Knight and Ms. Weiler.
(2)
The below tables represent the compensation actually paid calculation detail:

 

 

First PEO - Ido Schoenberg

 

 

Second PEO - Roy Schoenberg

 

 

NON-PEO NEOs

 

Compensation Element

 

2024

 

 

2024

 

 

2024

 

SCT Reported Total Compensation

 

$

2,115,004

 

 

$

2,682,079

 

 

$

4,043,689

 

(i) Aggregate SCT Reported Equity Compensation (-)

 

$

-

 

 

$

-

 

 

$

2,681,368

 

(ii) Year-End Fair Value of Awards Granted During the FY & Outstanding (+)

 

$

-

 

 

$

-

 

 

$

365,033

 

(iii) Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Outstanding (+)

 

$

(1,459,802

)

 

$

(1,414,000

)

 

$

(147,318

)

(iv) Vesting Date Fair Value of Awards Granted & Vested During the Covered FY (+)

 

$

-

 

 

$

-

 

 

$

807,098

 

(v) Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Vesting During Covered FY (+)

 

$

(67,582

)

 

$

(116,750

)

 

$

(335,438

)

(vi) Prior FYE Value of Awards Determined to Fail to Meet Vesting Conditions During Covered FY (-)

 

$

-

 

 

$

-

 

 

$

527,514

 

Compensation Actually Paid Determination

 

$

587,620

 

 

$

1,151,329

 

 

$

1,524,182

 
(3)
Equity compensation fair value calculated based on assumptions determined in accordance with FASB ASC Topic 718.
(4)
Total shareholder return calculated based on an assumed $100 investment as of September 17, 2020 and the reinvestment of any issued dividends.
(5)
The peer group reflected in the tables above is the S&P 500 Health Care Services index total shareholder return calculated based on an assumed $100 investment as of September 17, 2020 and the reinvestment of any issued dividends.
        
Named Executive Officers, Footnote
(1)
Amwell’s first principal executive officer for FY2020 through FY2024 was Dr. Ido Schoenberg. Amwell’s second principal executive officer for FY2020 through FY2024 was Dr. Roy Schoenberg. Amwell’s other, non-PEO, NEOs for FY2020 were Ms. Gotlib, Kurt Knight, and Mr. Anderson. Amwell’s other, non-PEO, NEOs for FY2021 were Ms. Gotlib, Mr. Shepardson, Mr. Knight, Mr. O’Grady, and Mr. Anderson. Amwell’s other, non-PEO, NEOs for FY2022 were Ms. Gotlib, Mr. Shepardson, Mr. Knight, and Mr. Paunovich. Amwell’s other, non-PEO, NEOs for FY2023 were Ms. Gotlib, Mr. Shepardson, Mr. Paunovich and Ms. Weiler. Amwell’s other, non-PEO, NEOs for FY2024 were Mr. Shepardson, Mr. Hirschhorn, Ms. Gotlib,Mr. Knight and Ms. Weiler.
       
Peer Group Issuers, Footnote
(5)
The peer group reflected in the tables above is the S&P 500 Health Care Services index total shareholder return calculated based on an assumed $100 investment as of September 17, 2020 and the reinvestment of any issued dividends.
        
Non-PEO NEO Average Total Compensation Amount $ 4,043,689 $ 3,081,641 $ 6,417,175 $ 5,756,009 $ 9,574,620
Non-PEO NEO Average Compensation Actually Paid Amount $ 1,524,182 22,839 2,418,932 (3,538,060) 21,760,358
Equity Valuation Assumption Difference, Footnote
(3)
Equity compensation fair value calculated based on assumptions determined in accordance with FASB ASC Topic 718.
        
Compensation Actually Paid vs. Total Shareholder Return

img152362001_4.jpg

        
Compensation Actually Paid vs. Net Income

img152362001_5.jpg

        
Compensation Actually Paid vs. Company Selected Measure

img152362001_6.jpg

        
Tabular List, Table

Provided below are the most important financial measures used to link compensation actually paid with Amwell performance during the most recently completed fiscal year:

Revenue

Stock Price Milestones

Subscription Bookings

DHA Bookings
       
Total Shareholder Return Amount $ 2 6 12 26 110
Peer Group Total Shareholder Return Amount 129 157 170 162 119
Net Income (Loss) $ (212,638,000) (679,200,000) (272,100,000) (176,800,000) (228,600,000)
Adjustment to PEO and Non PEO Compensation Footnote [Text Block]
(2)
The below tables represent the compensation actually paid calculation detail:

 

 

First PEO - Ido Schoenberg

 

 

Second PEO - Roy Schoenberg

 

 

NON-PEO NEOs

 

Compensation Element

 

2024

 

 

2024

 

 

2024

 

SCT Reported Total Compensation

 

$

2,115,004

 

 

$

2,682,079

 

 

$

4,043,689

 

(i) Aggregate SCT Reported Equity Compensation (-)

 

$

-

 

 

$

-

 

 

$

2,681,368

 

(ii) Year-End Fair Value of Awards Granted During the FY & Outstanding (+)

 

$

-

 

 

$

-

 

 

$

365,033

 

(iii) Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Outstanding (+)

 

$

(1,459,802

)

 

$

(1,414,000

)

 

$

(147,318

)

(iv) Vesting Date Fair Value of Awards Granted & Vested During the Covered FY (+)

 

$

-

 

 

$

-

 

 

$

807,098

 

(v) Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Vesting During Covered FY (+)

 

$

(67,582

)

 

$

(116,750

)

 

$

(335,438

)

(vi) Prior FYE Value of Awards Determined to Fail to Meet Vesting Conditions During Covered FY (-)

 

$

-

 

 

$

-

 

 

$

527,514

 

Compensation Actually Paid Determination

 

$

587,620

 

 

$

1,151,329

 

 

$

1,524,182

 
       
Revenue $ 254,364,000 259,047,000 277,190,000 252,789,000 245,265,000
Measure:: 1          
Pay vs Performance Disclosure          
Name Revenue        
Measure:: 2          
Pay vs Performance Disclosure          
Name Stock Price Milestones        
Measure:: 3          
Pay vs Performance Disclosure          
Name Subscription Bookings        
Measure:: 4          
Pay vs Performance Disclosure          
Name DHA Bookings        
Ido Schoenberg [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount $ 2,115,004 797,800 16,161,230 39,988,708 69,253,101
PEO Actually Paid Compensation Amount $ 587,620 $ (9,131,552) $ 7,075,701 $ (26,819,435) $ 96,113,239
PEO Name Dr. Ido Schoenberg Dr. Ido Schoenberg Dr. Ido Schoenberg Dr. Ido Schoenberg Dr. Ido Schoenberg
Roy Schoenberg [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount $ 2,682,079 $ 658,400 $ 16,044,010 $ 39,940,379 $ 69,247,314
PEO Actually Paid Compensation Amount $ 1,151,329 $ (9,270,952) $ 6,958,481 $ (26,867,764) $ 96,107,452
PEO Name Dr. Roy Schoenberg Dr. Roy Schoenberg Dr. Roy Schoenberg Dr. Roy Schoenberg Dr. Roy Schoenberg
PEO | Ido Schoenberg [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (1,459,802)        
PEO | Ido Schoenberg [Member] | Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Vesting During Covered FY [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (67,582)        
PEO | Roy Schoenberg [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,414,000)        
PEO | Roy Schoenberg [Member] | Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Vesting During Covered FY [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (116,750)        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,681,368        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 365,033        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (147,318)        
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 807,098        
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 527,514        
Non-PEO NEO | Year-Over-Year Change in Fair Value of Awards Granted During Prior FY & Vesting During Covered FY [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (335,438)